International AIDS Society

Advances in PrEP options and HIV vaccine research unveiled at HIVR4P 2024, the 5th HIV Research for Prevention Conference

The IAS calls on stakeholders to put people first and ensure fast and equitable access to lenacapavir for all those in need.

Take a look at some of the late-breaking science you can see at the only global scientific conference focused on HIV prevention research.

IAS urges rapid vaccine delivery, free testing and clear non-stigmatizing messaging.

The IAS also announced newly elected members of its Governing Council, which determines strategy and policy direction for the organization.

This new format opens with Sharon Lewin, the IAS President, walking us through the latest HIV science released at AIDS 2024.

The results confirm that lenacapavir demonstrated 100% efficacy for HIV prevention in cisgender women.

7th known individual cured of HIV and a successful trial of a twice-yearly HIV prevention shot announced at conference

New global HIV projections and advances in STI and HIV pre-exposure prophylaxis also unveiled ahead of AIDS 2024.

AIDS 2024 offers more than 200 sessions that spotlight the latest science, insights and lessons for and from the global HIV response.

Here is a preview of HIV treatment and cure research highlights you can expect.

The Global Village has something for everyone!

Take a look at some of the policy research highlights you can expect at the world’s largest conference on HIV and AIDS.

Browse over 200 sessions, including plenary presentations, invited-speaker symposia, oral abstract sessions, workshops and more.

The conference will spotlight challenges and opportunities in some of the world’s most HIV-affected regions.

Ahead of #AIDS2024, it’s time to start a conversation about what a person-centered and human rights-based HIV response looks like!

The IAS is concerned about the law keeping communities away from accessing HIV services.